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Introduction
Gout, an inflammatory arthritis caused by elevated serum uric acid
levels, is emerging as a significant risk factor for cardiovascular
disease (CVD). Recently, a nurse practitioner (NP) was caring for a
patient who was suffering from a particularly severe gout attack
while being treated in the ICU for new onset Atrial Fibrillation. The
patient reported that he had never had an attack this severe before.
He asked the NP if his history of gout could be related to his recent
heart problems. The nurse practitioner, in order to answer the
patient’s question, spent time researching the disease process of
gout, as well as, the possibility of association between gout and
cardiovascular disease. She learned that current research provides
clear evidence that gout is a risk factor for CVD. In the course of her
research, she advanced her knowledge of the pathophysiology of
gout and the significance of gout’s risk for CVD. Finally, utilizing this
knowledge will help her to manage the care of patients with gout and
cardiovascular disease.

Presentation of Case Study
L. B. is a 64 year old male hospitalized in the Intensive Care Unit
(ICU) for new onset Atrial Fibrillation. On his second day in the
hospital, L. B. underwent a stress test, which he ultimately failed.
Eight hours after the stress test, L. B. developed severe pain, redness,
and swelling in bilateral hands, wrists, feet, and ankles. The patient
was given Furosemide 20mg IVP, which did not alleviate the swelling
and pain. Finally, it was identified that he was experiencing an
episode of acute inflammation (EAI) of gout and he was given
Methelprednisone 60mg IVP. This relieved the swelling and pain
enough that he could be discharged. Ultimately, L. B. underwent
cardiac catheritization where he received a stent for an 80%
occlusion to his circumflex artery.
L. B. has a medical history of atrial fibrillation, gouty arthritis,
hyperlipidemia, and GERD. Surgical history reveals left knee
replacement (2015), left rotator cuff repair (2008), right rotator cuff
repair (2004), and right knee replacement (1997). Current
medications are Plavix 75mg, Sotalol 80 mg, Colchicine 0.6mg,
Allopurinol 300mg, and Coumadin 2mg.

Signs and Symptoms
There are two phases of gout: acute and chronic. Each phase has distinct
signs and symptoms (Perez-Ruiz, Castillo, Chinchilla, & Herrero-Beites, 2014,
p. 194).
Phase 1: Acute gout- episodes of acute inflammation (EAI)
●
●
●
●
●
●
●
●

sudden onset of symptoms
pain – most severe in the first 12 – 24 hours
erythema (localized redness)
inflammation of soft tissue of articular and periarticular joint
structures
most commonly affected joint is the first metatarsophalangeal
(MTP) joint of the lower limbs - classic podagra (the hallmark
symptom of gout)
most commonly affected upper limb joint is the olecranon bursa.
Hands can also be affected.
monoarticular distribution (single structure involvement) is the
most common.
nocturnal onset most common

Pathophysiology of gout
High levels of serum urate, hyperuricemia, is the main cause of gout.
Hyperuricemia is when serum uric acid levels are greater than 7.0 mg/dL.
Elevated serum uric acid levels can occur from two different causes:
overproduction of hepatic urate through purine synthesis de novo and
salvage pathways or renal under excretion of uric acid.

A direct and indirect association between the pathophysiology
of gout and the risk for developing CVD has been well established
by past and current research. Unfortunately, gout is a common
condition. In fact, gout is one of the most common conditions seen
by practitioners. Its prevalence is higher than rheumatoid arthritis
and in some studies it’s equal to fibromyalgia and more prevalent
than kidney disease, liver disease and prostate cancer in annual
primary care visits in the United States (Vannucchi, 2012, p. 192).
Therefore, as the incidence of gout increases in the population, so
is the risk for CVD increasing. It is imperative that practitioners
recognize this vital association so they can be prepared to treat a
patient’s gout and assess for CVD risk.

A thorough knowledge of the phases of the disease is required
to effectively manage gout (Hardy, 2011, p. 19). Not only must
the NP efficiently and effectively treat the EAIs of gout, but also
manage the chronic inflammation as well. Furthermore, because
of the well documented association between gout and
cardiovascular disease, the nurse practitioner must evaluate a
patient with the diagnosis of gout for the increased risk of CVD.
For example, if a patient presents with acute symptoms of gout,
there should be an automatic assessment for CVD. The
assessment for cardiovascular risk factors should then lead to
patient education about the increased future risk for
cardiovascular disease (Bhole & Krishnan, 2014, p. 141).

Conclusion

Phase 2: Chronic gout – persistent or nonacute
● palpable tophi (macroscopic aggregate of monosodium urate crystals
[MSUCs])
● gouty arthropathy – persistent joint limitations
● chronic gouty arthritis – persistent joint swelling
● joint deformity
● oligoarticular and polyarticular distribution may occur if gout is
severe, persistent and untreated for an extended length of
time.
● increased risk for cardiovascular disease

Significance of Pathophysiology

Implications for Nursing Care

Fig. 3. (A) Rapid development of extended intradermal tophi in the
fingerpads in a patient with serum urate level >12 mg/dL caused by
chronic kidney disease and chronic heart failure on high-dose diuretics
(Perez-Ruiz et al., 2014, p. 197).

Underlying Pathophysiology

Figure 1.
This is a picture of L.B.’s right foot and ankle shortly after discharge
from the ICU. This picture was provided by L. B. and permission for
the picture to be printed was obtained from L. B.

Additionally, there is a hereditary component to the ability of certain
populations in renal uric handling of acid and hyperuricemia (87% for
fractional excretion of uric acid, 60% for serum urate) (Merriman, Choi, &
Dalbeth, 2014, p. 280).
As the level of urate in the blood increases, it precipitates and forms
monosodium urate (MSU) crystals. MSU crystals, once deposited in the
tissues and synovial space of the joint, initiates an acute inflammatory
response. The inflammatory response attracts leukocytes to hte synovial
space and phagocytize the MSU crystals. This releases destructive
enzymes that cause more inflammation and tissue damage.

Fig. 7. Direct and indirect causal pathways linking hyperuricemia, gout,
and CVD. MSU, monosodium urate. (Bhole & Krishnan, 2014, p. 140).
Pathophysiology of gout as a risk factor for cardiovascular disease
Over time, this chronic form of inflammation [gout] can perceivably
increase the risk of CVD (Bhole & Krishnan, 2014, p. 126). There are
several mechanisms that explain the association between gout and CVD.
The direct pathway starts with hyperuricemia to deposition of MSU crystals
into the synovial spaces of joints. This results in chronic low-grade
inflammation which promotes atherogenesis and thrombogenesis.
Additionally, there are reports that link hyperuricemia with greater
coronary artery calcifications (Bhole & Krishnan, 2014, p. 126). Ultimately,
untreated high levels of uric acid in the blood will increase the patient’s risk
for CVD.
The indirect pathway proves that there are shared risk factors for gout
and CVD. Research has shown that patients with gout also have the same
risk factors for CVD. These include: male gender, age, diabetes,
hypertension, obesity, alcohol consumption, metabolic syndrome, and
menopause (Bhole & Krishnan, 2014, p. 139).

Thorough research has provided knowledge about gout and its
association with increased risk of cardiovascular disease for both
the nurse and the patient. After sharing what she learned, the
nurse and the patient discussed how to decrease his risk for future
EAIs and for CVD. She provided education on how he can modify
his diet, exercise, medications, etc. Utilizing this knowledge, its
significance and practice implications, the nurse is better prepared
to care for future patients suffering from gout and CVD.
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